Clinical Perspective on AE Tolerance

Opinion
Video

Focusing on patients with multiple myeloma who receive GPRC5D-targeted therapy, Beth Faiman, CNP, PhD, discusses how long-term treatment impacts patients’ tolerance to adverse events.

Recent Videos
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
Related Content